Abstract
Sequential administration of the association of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel could be better tolerated than the association of an anthracycline and paclitaxel while having a similar antitumour effect. 69 patients with advanced breast cancer previously untreated with anthracyclines or paclitaxel entered a phase II multicentre study in which FEC was followed by paclitaxel. Both regimens were administered 4 times every 21 days. The median follow-up is 20 months and 38/69 patients have died. Grade III–IV toxicity was acceptable. Leukopenia occurred in 26% of patients, thrombocytopenia in 2% and anaemia in 4%. One patient had reversible heart failure during FEC therapy. Peripheral neuropathy and arthralgia-myalgia occurred in 9% and 4% of patients, respectively and one patient had respiratory hypersensitivity during paclitaxel treatment. 9 patients did not complete therapy because of: treatment refusal (n= 1), cardiac toxicity (n= 1), early death during FEC chemotherapy (n= 1), major protocol violations (n= 4), hypersensitivity reaction (n= 1) and early death during paclitaxel chemotherapy (n= 1). The overall response rate was 65% (95% CI = 53–76), and 7% of patients had stable disease. Therapy was defined as having failed in 28% of patients because they were not evaluable (13%) or had progressive disease (15%). The median time to progression and survival are 13.2 and 23.5 months, respectively. Sequential FEC-paclitaxel is a suitable strategy for patients with metastatic breast cancer who have not been previously treated with anthracyclines and/or taxanes. In fact, it avoids major haematologic toxicity and has a good antitumour effect. © 2001 Cancer Research Campaign www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Batel-Copel LM, Kornblith AB, Batel PC and Holland JC (1997) Do oncologists have an increasing interest in the quality of life of their patients? A literature review of the last 15 years. Eur J Cancer 33: 29–32
Biganzoli L and Piccart MJ (1997) The bigger the better?...or what we know and what we still need to learn about anthracycline dose per course, dose density and cumulative dose in the treatment of breast cancer. Ann Oncol 8: 1177–1182
Bishop JF, Dewar J, Toner GC, Smith J, Tattersall MH, Olver IN, Ackland S, Kennedy I, Goldstein D, Gurney H, Walpole E, Levi J, Stephenson J and Canetta R (1999) Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 17: 2355–2364
Cocconi G, Bisagni G, Bella M, Acito L, Anastasi P, Carpi A, Di Costanzo F, Frassoldati A, Mosconi A, Borrini A and Buzzi P (1999) Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study. Am J Clin Oncol 22: 593–600
Coombes RC, Bliss JM, Wils J, Morvan F, Espie M, Amadori D, Gambrosier P, Richards M, Aapro M, Villar-Grimalt A, McArdle C, Perez-Lopez FR, Vassilopoulos P, Ferreira EP, Chilvers CE, Coombes G, Woods EM and Marty M (1996) Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. J Clin Oncol 14: 35–45
Curran D, Aaronson N, Standaert B, Molenberghs G, Therasse P, Ramirez A, Koopmanschap M, Erder H and Piccart M (2000) Summary measures and statistics in the analysis of quality of life data: an example from an EORTC-NCIC-SAKK locally advanced breast cancer study. Eur J Cancer 36: 834–844
Falkson G, Gelman RS, Pandya KJ, Osborne K, Tormey D, Cummings F, Sledge GW and Abeloff MD (1998) Eastern Cooperative Oncology Group randomized trial of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol 16: 1669–1676
Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, Tinazzi A and Liberati A (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16: 3439–3460
Gehl J, Boesgaard M, Paaske T, Jensen BV and Dombernowsky P (1996) Paclitaxel and doxorubicin in metastatic breast cancer. Semin Oncol 23: 35–38
Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK and Hortobagyi GN (1991) Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797–1805
Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, MacKenzie R, Robert J, Ottaway J, Burnell M, Williams CK and Tu D (1998) Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16: 2651–2658
Muss HB, Case LD, Richards F, White DR, Cooper MR, Cruz JM, Powell BL, Spurr CL and Capizzi RL the Piedmont Oncology Association (1991) Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. NEJM 325: 1342–1348
Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, Klaassen U, Namer M, Bonneterre J, Fumoleau P and Winograd B (1996) Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14: 1858–1867
Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JW, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PS, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M and Aapro M for the 304 Study Group (1999) Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 17: 1413–1424
Pazos C, Mickiewicz E, Di Notto MR, Coppola F, Ventriglia M, Jovtis S, Balbiani L, Lewi D, Rondinon M, Temperley G, Trigo M, Bertoncin AM, Pascual M, Uranga G, Cazap E, Breier S, Grasso S, Estevez R, Triguboff E, Alvarez A and Suarez A (1999) Phase II of doxorubicin/taxol in metastatic breast cancer. Breast Cancer Res Treat 55: 91–96
Pivot X, Asmar L and Hortobagy GN (1999) The efficacy of chemotherapy with docetaxel and paclitaxel in anthracyclin-resistant breast cancer. Int J Oncol 15: 381–386
Pouillart P, Fumoleau P and Romieu G (1999) Final results of a phase II randomized, parallel study of doxorubicin/cycclophosphamide and doxorubicin/Taxol (paclitaxel) as neoadjuvant treatment of local-regional breast cancer [abstract]. Proc Am Soc Clin Oncol 18: 73a
Rahman ZU, Frye DK, Smith TL, Asmar L, Theriault RL, Buzdar AU and Hortobagyi GN (1999) Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy. Cancer 85: 104–111
Reichman BS, Seidman AD, Crown JP, Heelan R, Hakes TB, Lebwohl DE, Gilewski TA, Surbone A, Currie V and Hudis CA (1993) Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11: 1943–1951
Riccardi A, Tinelli C, Pugliese P, Brugnatelli S, Giordano M, Danova M, Richetti A, Fava S, Nastasi P, Rinaldi E, Fregoni V, De Monte A and Trotti G (for the Cooperative Group of Study and Treatment of Breast Cancer) (2000) Doubling the epirubicin dosage in the 5-fluorouracil, epirubicin and cyclophosphamide (FEC) regimen for advanced breast cancer: a prospective, randomized, multicentric study on antitumor effect and life quality. Int J Oncol 16: 769–776
Rischin D, Smith J, Millward M, Lewis C, Boyer M, Richardson G, Toner G, Gurney H and McKendrick J (2000) A phase II trial of paclitaxel and epirubicin in advanced breast cancer. Br J Cancer 83: 438–442
Rivera E, Holmes FA, Frye D, Valero V, Theriault RL, Booser D, Walters R, Buzdar AU, Dhingra K, Fraschini G and Hortobagyi GN (2000) Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy. Cancer 89: 2195–2201
Sledge GWJ, Neuberg D, Ingle J, Martino S and Wood W (1997). Phase III trial of doxorubicin (A) vs paclitaxel (T) vs doxorubicin+paclitaxel (A + T) as first line therapy for metastatic breast cancer (MBC): an intergroup trial), Proc Am Soc Clin Oncol 16,
Sparano JA, Hu P, Rao RM, Falkson CI, Wolff AC and Wood WC (1999) Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 17: 3828–3834
Venturini M, Lunardi G, Del Mastro L, Vannozzi MO, Tolino G, Numico G, Viale M, Pastrone I, Angiolini C, Bertelli G, Straneo M, Rosso R and Esposito M (2000) Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity. J Clin Oncol 18: 2116–2125
Winer EP, Morrow M, Osborne CK and Harris JR (2001) Malignant tumors of the breast. Cancer Principles and practice of Oncology (6th Ed), De Vita VT, Hellman S, Rosenberg SA (eds). pp. 1651–1716, Lippincott Williams and Wilkins: Philadelphia
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Riccardi, A., Pugliese, P., Danova, M. et al. A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01). Br J Cancer 85, 141–146 (2001). https://doi.org/10.1054/bjoc.2001.1897
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1897
Keywords
This article is cited by
-
Impact of chemotherapy schedule modification on breast cancer patients: a single-centre retrospective study
International Journal of Clinical Pharmacy (2020)
-
Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy
Cancer Chemotherapy and Pharmacology (2005)